Source-grounded facts extracted from Insight Molecular Diagnostics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Gisela Paulsen departed as President and Chief Operating Officer at Insight Molecular Diagnostics Inc..
“the positions occupied by Gisela Paulsen, President and Chief Operating Officer, and Douglas Ross, Chief Scientific Officer, will be eliminated.”
Joshua Riggs was appointed as Interim Chief Executive Officer at Insight Molecular Diagnostics Inc..
“and the appointment of Joshua Riggs as Interim Chief Executive Officer of the Company, effective as of December 2, 2022.”
Ronald Andrews departed as President and Chief Executive Officer at Insight Molecular Diagnostics Inc..
“On November 30, 2022, Oncocyte Corporation (the “Company”) issued a press release announcing that Ronald Andrews will step down from his role as President and Chief Executive Officer and director of the Board of Directors of the Company (the “Board”), effective as of December 1, 2022”
Melinda Griffith resigned as Director at Insight Molecular Diagnostics Inc..
“On November 19, 2022, Melinda Griffith notified the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”) of her resignation from the Board, effective January 1, 2023.”
Insight Molecular Diagnostics Inc. reported the three and nine months ended September 30, 2022 results: revenue $1.0 million, net income $9.3 million, EPS $0.08.
“from the past few years transition to market launches of several new high-value, reimbursed tests over coming quarters.” Third Quarter 2022 Financial Results Total revenue was $1.0 million for the third quarter of 2022, compared to $2.1 million for the prior quarter. Third quarter revenues associated with DetermaRx were $1.0 million, an increase of $0.1 million”
Insight Molecular Diagnostics Inc.: Adopted Second Amended and Restated Bylaws on November 3, 2022, allowing the Company to appoint a President or Presidents without requiring the CEO to also be a President (effective 2022-11-03).
“On and effective as of November 3, 2022, the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”) approved and adopted the Second Amended and Restated Bylaws of the Company (the “Bylaws”), pursuant to which the Company may appoint a President or Presidents without requiring that the chief executive officer also be a President.”
James Liu was appointed as Controller & Principal Accounting Officer at Insight Molecular Diagnostics Inc..
“Effective September 20, 2022, Oncocyte Corporation (“Oncocyte” or the “Company”) appointed James Liu as the Company’s Controller & Principal Accounting Officer.”
Anish John was appointed as Chief Financial Officer at Insight Molecular Diagnostics Inc..
“Effective August 8, 2022, the Board of Directors of the Company appointed Gisela Paulsen to the position of President and Chief Operating Officer and Anish John to the position of Chief Financial Officer.”
Gisela Paulsen was appointed as President and Chief Operating Officer at Insight Molecular Diagnostics Inc..
“Effective August 8, 2022, the Board of Directors of the Company appointed Gisela Paulsen to the position of President and Chief Operating Officer and Anish John to the position of Chief Financial Officer.”
John Peter Gutfreund was elected as Director at Insight Molecular Diagnostics Inc..
“Effective July 28, 2022, the Board of Directors (the “Board”) of Oncocyte Corporation (“Oncocyte” or the “Company”) elected John Peter Gutfreund, age 36, to serve as a director on the Board, with a term that expires at the Annual Meeting of Shareholders of the Company to be held in 2023 or until his earlier resignation or removal.”
Li Yu resigned as Vice President, Controller, and Principal Accounting Officer at Insight Molecular Diagnostics Inc..
“Effective June 24, 2022, Li Yu resigned as Vice President, Controller, and Principal Accounting Officer of the Company.”
Anish John was appointed as Senior Vice President, Finance, and Interim Chief Financial Officer at Insight Molecular Diagnostics Inc..
“Anish John, our Vice President, Operations – Transplant, has been appointed Senior Vice President, Finance, and Interim Chief Financial Officer effective June 1, 2022.”
Mitchell Levine changed role as Chief Financial Officer at Insight Molecular Diagnostics Inc..
“Mitchell Levine, our Chief Financial Officer since 2017, will no longer serve in that capacity as of June 1, 2022.”
Andrew Arno was appointed as Chairman of the Board at Insight Molecular Diagnostics Inc..
“the Board has appointed Andrew Arno as Chairman of the Board effective May 6, 2022.”
Cavan Redmond changed role as Chairman of the Board at Insight Molecular Diagnostics Inc..
“Mr. Redmond has stepped down as Chairman of the Board, and that the Board has appointed Andrew Arno as Chairman of the Board effective May 6, 2022.”
Gisela Paulsen was appointed as Chief Operating Officer at Insight Molecular Diagnostics Inc..
“We have appointed Gisela Paulsen as Chief Operating Officer effective October 4, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.